last authored:
last reviewed:
The average platelet lifespan is 7-10 days. Even given this short duration, because of constant bone marrow production, normal platelet counts are 150-400 x 109/L. A count below 150 x 109/L is termed thrombocytopenia, and is very common amongst hospitalized patients. This can be caused by decreased production, increased destruction, or increased sequestration.
Betty is a 7 year-old girl who presents with a petechial rash following a viral infection. Her family physician orders bloodwork, showing a platelet count of 74 x 109/L.
The many causes of thrombocytopenia can be grouped into five major categories:
decreased production
|
decreased platelet survival (immune-mediated)
|
decreased platelet survival (non- immune-mediated)
|
increased sequestration
hemodilution
|
Spontaneous bleeding, especially highly vascularized mucous membranes, skin, and genitourinary tract, can occur in levels below 10x109/L.
Abdominal exam can reveal increased splenomegaly or signs of liver disease.
Bone marrow aspiration can be helpful in distinguishing between decreased production and increased destruction. In decreased production, megakaryocytes will be decreased or absent, and offending cells (ie with malignancy) may also be seen. With increased destruction, megakaryocyte number will be increased.
Reticulated platelet count is a blood test measuring young platelets (via their enriched RNA content) and can assess platelet kinetics. Numbers will be decreased if production is down, but will be increased, as a percentage, if destruction is up.
Platelet transfusions may be used if thrombocytopenia is due to bone marrow dysfunction, with a trigger level of 10x109/L.
If splenomegaly is the cause for thrombocytopenia, splenectomy can be helpful. This decreases destruction and sequestration, as well as antibody production.
Imunosuppressants, such as corticosteroids, can be useful if thrombocytopenia is immune-mediated.
works by inhibiting the Fcgamma receptor on macrophages
some IVIG recognizes host RBCs,
increases inhibitory Fcgamma2 receptors.
created:
authors:
editors:
reviewers: